TruSight Tumor 15 uses next-generation sequencing (NGS) technology to provide a comprehensive assessment of 15 genes that are commonly mutated in solid tumors. It accurately detects low-frequency variants from 20 ng of starting DNA and is optimized for formalin-fixed, paraffin-embedded (FFPE) tumor tissue. Featuring a rapid workflow that can be easily integrated into lab procedures, this panel offers a single assay for accurate, economical, and rapid analysis of solid tumors.
This TruSight Tumor panel offers:
View the gene list »
3 human references samples and 5 FFPE-exacted DNA samples from lung, colon, melanoma, and breast tumors were prepared using TruSight Tumor 15 Kit. These libraries were sequenced on the MiniSeq System using a high output kit at a 2 x 150 bp read length configuration with dual indexing. The total yield was 7.6 Gb with 94.9% of bases at or above Q30.
For Research Use Only. Not for use in diagnostic procedures.
|Description||Document Type||File Info|
|Illumina VariantStudio Data Analysis Software||Data Sheet||PDF(2 MB)|
|TruSight Tumor 15||Data Sheet||PDF(< 1 MB)|
Catalog IDs: OP-101-1001, OP-101-1002
View the TruSight Tumor 15 support page for additional technical information.
Kit requires MiSeq Software v2.6 or higher and the Illumina Annotation Engine. Download files »